source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
The Motley Fool | 2021-08-17 06:22:00 | https://www.fool.com/investing/2021/08/17/3-top-biotech-stocks-to-buy-in-august/ | Each of these companies makes for a great vehicle to play an aging demographic. | 3 Top Biotech Stocks to Buy in August | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-08-17 02:12:39 | https://www.benzinga.com/general/biotech/21/08/22527721/apple-gm-kroger-abbvie-merck-bristol-myers-squibb-biogen-how-warren-buffetts-berkshire-adjusted-i | Warren Buffett-led Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) sharply lowered its exposure in General Motors Co (NYSE: GM), Merck & Co Inc (NYSE: MRK), AbbVie Inc (NYSE: ABBV), Bristol-Myers Squibb Co (NYSE: BMY) and added positions in Kroger Inc (NYSE: KR) and Aon Plc (NYSE: AON), in the second quarter, regula... | Apple, GM, Kroger, AbbVie, Merck, Bristol Myers Squibb, Biogen — How Warren Buffett's Berkshire Adjusted Its Portfolio In Q2 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Kiplinger | 2021-08-16 19:23:02 | https://www.kiplinger.com/investing/stocks/603290/stocks-warren-buffett-buying-selling-q2-2021 | Berkshire Hathaway CEO Warren Buffett and his team were bears yet again in Q2 2021, hacking away at a large number of positions while only adding to a handful. | 11 Stocks Warren Buffett Is Selling (And 3 He's Buying) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2021-08-16 19:13:20 | https://www.youtube.com/watch?v=5xn8ci6vtBc | Retailers are on deck to report earnings this week, but some macro headwinds could create uncertainty for the group. | Digging into the moves in big cap pharma | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2021-08-16 17:41:00 | https://www.reuters.com/article/us-investment-funds-berkshire/buffetts-berkshire-pares-drug-holdings-sheds-axalta-biogen-idUSKBN2FH2C6 | Warren Buffett's Berkshire Hathaway Inc said on Monday it trimmed or eliminated its stakes in several pharmaceutical companies, and reported a small new stake in a Merck & Co spinoff, Organon & Co. | Buffett's Berkshire pares drug holdings, sheds Axalta, Biogen | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-15 23:00:00 | https://www.fool.com/investing/2021/08/15/better-dividend-stock-abbvie-or-pfizer/ | Both of these big pharma stocks have plenty to offer investors. | Better Dividend Stock: AbbVie or Pfizer? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-15 10:00:00 | https://seekingalpha.com/article/4449525-10-dividend-growth-stocks-for-august-2021 | This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for consideration. | 10 Dividend Growth Stocks For August 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-13 06:22:00 | https://www.fool.com/investing/2021/08/13/what-rinvoqs-positive-news-means-for-abbvie/ | If the drug can overcome JAK inhibitor-class concerns, it could capture share in the growing atopic dermatitis market. | What Rinvoq's Positive News Means for AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-10 06:35:00 | https://www.fool.com/investing/2021/08/10/3-key-takeaways-from-abbvies-second-quarter-earnin/ | The company's future looks increasingly bright. | 3 Key Takeaways From AbbVie's Second-Quarter Earnings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-09 15:48:34 | https://seekingalpha.com/article/4447345-abbvie-strong-earnings-make-bull-case-for-reassuringly-undervalued-pharma | AbbVie management has set itself the tough challenge of dealing with the patent expiry of $20bn selling Humira while maintaining top-line revenue growth. | AbbVie: Strong Earnings Make Bull Case For Reassuringly Undervalued Pharma | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-08-09 13:50:29 | https://www.benzinga.com/general/biotech/21/08/22404180/abbvie-mission-therapeutics-pick-alzheimers-parkinsons-targets-in-neurodegenerative-disease-colla | AbbVie Inc (NYSE: ABBV) has advanced its collaboration with privately-held Mission Therapeutics, with the nomination of two DUB targets to take into the next stage of drug discovery. This selection follows supportive data from in vitro and in vivo Alzheimer's and Parkinson's disease models. | AbbVie, Mission Therapeutics Pick Alzheimer's & Parkinson's Targets In Neurodegenerative Disease Collaboration | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-09 09:00:00 | https://seekingalpha.com/article/4446970-abbvie-undervalued-dividend-stock-huge-pipeline-possibilities | For the past decade, AbbVie has sequentially increased its revenue YoY, driving annual increases in gross profits and billions upon billions in annual profits. AbbVie just came off a record 2020 year for revenue and smashed Q2 generating $13.96 billion of revenue, an increase of 33.9% YoY and raised fiscal 2021 guidanc... | AbbVie: An Undervalued 4.52% Dividend Machine With A Huge Pipeline Of Possibilities | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-08-09 08:45:00 | https://www.prnewswire.com/news-releases/skyrizi-risankizumab-rzaa-now-available-in-the-us-as-a-single-150-mg-injection-for-adults-with-moderate-to-severe-plaque-psoriasis-301350489.html | NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that SKYRIZI® (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, is now available in the U.S. as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque psoriasis. | SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-09 08:26:20 | https://seekingalpha.com/article/4447130-wall-street-breakfast-podcast | Wall Street Breakfast (Podcast) | Wall Street Breakfast (Podcast) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-08-09 07:07:41 | https://www.benzinga.com/general/biotech/21/08/22394581/abbvie-returns-eye-drug-candidate-to-molecular-partners | AbbVie Inc (NYSE: ABBV) has terminated its license and collaboration agreement with Molecular Partners AG (NASDAQ: MOLN) for abicipar pegol for neovascular age-related macular degeneration (nAMD) and Diabetic Macular Edema (DME). As such, Molecular Partners will regain the development and commercial rights of abicipar... | AbbVie Returns Eye Drug Candidate To Molecular Partners | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-08-09 04:00:00 | https://www.businesswire.com/news/home/20210809005029/en/Mission-and-AbbVie-Collaboration-in-Alzheimer%E2%80%99s-and-Parkinson%E2%80%99s-Diseases-Reaches-Next-Milestone/ | CAMBRIDGE, England--(BUSINESS WIRE)--Mission Therapeutics (“Mission”), a drug discovery and development company focused on targeting the ubiquitin pathway, and AbbVie (“AbbVie”)(NYSE: ABBV) today announced progression of selected deubiquitylating enzyme (DUB) targets into the next phase of research in their neurodegene... | Mission and AbbVie Collaboration in Alzheimer's and Parkinson's Diseases Reaches Next Milestone | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-08 21:39:31 | https://seekingalpha.com/article/4447020-abbvie-diversified-strength-tempers-the-humira-patent-cliff-ahead | AbbVie's diversified & strong collection of products will temper the 2023 Humira patent cliff that could decline revenues by $9B. The market has factored in incredible risk from Humira by valuing AbbVie at just over 10 times free cash flow. | AbbVie: Diversified Strength Tempers The Humira Patent Cliff Ahead | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-08 11:30:59 | https://seekingalpha.com/article/4446838-3-reasons-we-like-abbvie-stock-abbv-today | In an overvalued market - AbbVie offers growing dividends for dividend-seeking investors, and it's still undervalued for value investors seeking value upside. AbbVie generates ample free cash to cover their debt, and they are ready to offset Humira's decline in 2023. | 3 Reasons We Like AbbVie Today | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-08 09:35:00 | https://seekingalpha.com/article/4445467-3-big-dividends-paying-monthly-for-your-retirement-base | A monthly income stream provides a lot of flexibility for the income investor. Monthly dividends makes DCA work even better. | 3 Big Dividends, Paying Monthly, For Your Retirement Basea | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-08 07:51:59 | https://seekingalpha.com/article/4446749-abbvie-similar-to-equity-bond-with-12-5-percent-yield | This article analyzes AbbVie Inc. under the framework of perpetual growth and Buffett's 10x Pretax Rule. Based on such examination, ABBV presents excellent prospects for offering double-digit return in the long term with a wide margin of safety. | AbbVie: Similar To Equity Bond With 12.5% Yield | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-08 07:37:30 | https://seekingalpha.com/article/4446747-abbvie-continued-performance | When AbbVie announced the acquisition of Allergan in 2019, I had reservations, but was upbeat as investors reacted with extreme caution. The acquisition of Allergan has been integrated well, as organic growth is solid and the Humira reliance is gradually coming down further. | AbbVie: Continued Performance | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-08-08 07:24:11 | https://247wallst.com/investing/2021/08/08/5-top-stocks-analysts-want-you-to-buy-now/ | 24/7 Wall St. reviews dozens of analyst research reports each day of the week with a goal of finding new ideas for investors and traders alike. | 5 Top Stocks Analysts Want You To Buy Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-08 05:52:00 | https://www.fool.com/investing/2021/08/08/here-are-the-12-best-dividend-stocks-i-own-right-n/ | All of them offer attractive dividends and solid growth prospects, too. | Here Are the 12 Best Dividend Stocks I Own Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-07 10:02:00 | https://www.fool.com/investing/2021/08/07/here-are-the-winners-of-cowens-big-pharma-rd-penta/ | The Wall Street firm put big drugmakers' R&D programs through five different tests. | Here Are the Winners of Cowen's Big Pharma R&D Showdown | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-05 17:17:27 | https://seekingalpha.com/article/4445642-collplant-cheap-game-changing-bio-printing-platform-company | CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company | CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-08-04 12:01:00 | https://www.prnewswire.com/news-releases/jama-dermatology-publishes-data-showing-rinvoq-upadacitinib-achieved-superiority-versus-dupixent-dupilumab-for-primary-and-all-ranked-secondary-endpoints-in-phase-3b-head-to-head-study-in-adults-with-atopic-dermatitis-301348484.html | NORTH CHICAGO, Ill., Aug. 4, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that JAMA Dermatology has published 24-week results from the Phase 3b Heads Up study evaluating the efficacy and safety of RINVOQ® (upadacitinib, 30 mg, once daily) versus DUPIXENT® (dupilumab, 300 mg, every other week) – both as mono... | JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Forbes | 2021-08-04 08:34:31 | https://www.forbes.com/sites/dividendchannel/2021/08/04/why-abbvie-is-a-top-25-dividend-giant/ | AbbVie has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a stunning $22.35B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 4.47% yield | Why AbbVie Is A Top 25 Dividend Giant | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-08-04 07:35:58 | https://247wallst.com/healthcare-business/2021/08/04/4-big-pharmaceutical-dividend-stocks-to-buy-as-yields-near-2021-lows/ | It has become the proverbial broken record. Every time it seems like yields on government securities will start trending higher, they roll over again. | 4 Big Pharma Dividend Stocks to Buy as Yields Near 2021 Lows | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-08-01 18:37:21 | https://seekingalpha.com/article/4443882-abbvie-stock-abbv-still-undervalued-with-more-room-to-grow | Abbvie - Still Undervalued With More Room To Grow | Abbvie - Still Undervalued With More Room To Grow | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-08-01 07:01:00 | https://www.fool.com/investing/2021/08/01/3-underrated-warren-buffett-stocks-smart-buys-now/ | They're either beaten down, bargains, or both. | 3 Underrated Warren Buffett Stocks That Are Smart Buys Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-07-30 17:52:06 | https://seekingalpha.com/article/4443372-abbvie-inc-abbv-ceo-rick-gonzalez-on-q2-2021-results-earnings-call-transcript | AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q2 2021 Results - Earnings Call Transcript | AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q2 2021 Results - Earnings Call Transcript | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-07-30 12:55:25 | https://www.zacks.com/stock/news/1771905/abbvie-s-abbv-q2-earnings-in-line-2021-guidance-raised | AbbVie (ABBV) matches second-quarter 2021 earnings estimates while beating the same for sales. Sales of new immunology drugs, Skyrizi and Rinvoq, reach $1 billion. | AbbVie's (ABBV) Q2 Earnings In Line, 2021 Guidance Raised | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-07-30 10:39:34 | https://www.zacks.com/stock/news/1771515/abbvie-abbv-q2-earnings-match-estimates | AbbVie (ABBV) delivered earnings and revenue surprises of 0.00% and 1.81%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock? | AbbVie (ABBV) Q2 Earnings Match Estimates | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-07-30 10:14:16 | https://www.fool.com/investing/2021/07/30/have-500-here-are-2-high-yielding-healthcare-stock/ | These two companies offer impressive -- and safe -- yields for investors who like income. | Have $500? Here Are 2 High-Yielding Healthcare Stocks to Consider | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-07-30 08:19:55 | https://www.benzinga.com/general/biotech/21/07/22245963/abbvie-q2-earnings-beats-consensus-slightly-guides-fy21-eps-below-consensus | AbbVie Inc (NYSE: ABBV) reports Q2 adjusted EPS of $3.11, marginally beating the consensus of $3.09. Overall sales increased 33.9% Y/Y to $13.9 billion, slightly ahead of the consensus of $13.6 billion. | AbbVie Q2 Earnings Beats Consensus Slightly; Guides FY21 EPS Below Consensus | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2021-07-30 08:17:52 | https://www.marketwatch.com/story/abbvie-cites-growth-of-immunology-business-in-the-second-quarter-2021-07-30 | AbbVie Inc. beat expectations for the second quarter of 2021, driven largely by gains in its immunology business. The drug maker had earnings of $766 million, or 42 cents per share, in the second quarter of 2021. | AbbVie cites growth of immunology business in the second quarter | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-07-30 07:53:17 | https://www.benzinga.com/news/earnings/21/07/22245350/recap-abbvie-q2-earnings | Shares of AbbVie (NYSE:ABBV) decreased 0.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 32.91% over the past year to $3.11, which beat the estimate of $3.09. | Recap: AbbVie Q2 Earnings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2021-07-30 07:49:00 | https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-raises-annual-profit-forecast-botox-demand-rebounds-2021-07-30/ | Drugmaker AbbVie Inc raised its full-year adjusted profit forecast on Friday, as demand soared for its Botox anti-wrinkle injection in the second quarter following the easing of COVID-19 restrictions. | AbbVie raises annual profit forecast as Botox demand rebounds | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-07-30 07:44:00 | https://www.prnewswire.com/news-releases/abbvie-reports-second-quarter-2021-financial-results-301345065.html | NORTH CHICAGO, Ill., July 30, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2021. | AbbVie Reports Second-Quarter 2021 Financial Results | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-07-29 23:28:57 | https://seekingalpha.com/article/4442864-5-blue-chip-bargains-that-create-the-worlds-safest-6-percent-yielding-retirement-portfolio | 5 Blue-Chip Bargains That Create The World's Safest 6% Yielding Retirement Portfolio | 5 Blue-Chip Bargains That Create The World's Safest 6% Yielding Retirement Portfolio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-07-29 10:35:12 | https://www.fool.com/investing/2021/07/29/how-abbvie-could-make-an-entry-into-this-rapidly-g/ | Venclexta's potential indication for the treatment of myelodysplastic syndrome could mean billions for AbbVie this decade. | How AbbVie Could Make an Entry Into This Rapidly Growing Drug Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-07-29 09:40:00 | https://www.fool.com/investing/2021/07/29/this-biotech-stock-is-too-cheap-to-ignore/ | Wall Street's short attention span has created an attractive entry point in this once-loved biotech. | This Biotech Stock Is Too Cheap to Ignore | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-07-29 08:31:00 | https://www.fool.com/investing/2021/07/29/market-crash-20-where-to-invest-1000/ | These two companies will be excellent buys in the event of another coronavirus-fueled market crash. | Market Crash 2.0: Where to Invest $1,000 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-07-27 10:48:55 | https://www.benzinga.com/general/biotech/21/07/22173909/abbvie-alphabet-founded-calico-extends-collaboration-focused-on-aging-age-related-diseases | AbbVie Inc (NYSE: ABBV) and Calico Life Sciences have collaborated to discover and develop new therapies for patients with age-related diseases, including neurodegeneration and cancer. It is the second extension of the collaboration initially established in 2014. | AbbVie, Alphabet-Founded Calico Extends Collaboration Focused on Aging, Age-Related Diseases | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2021-07-27 09:22:29 | https://marijuanastocks.com/abbv-and-calico-announce-second-extension-of-collaboration/ | AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and… The post AbbVie Inc. (ABBV) and Calico Announce Second Extension of Collaboration appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | AbbVie Inc. (ABBV) and Calico Announce Second Extension of Collaboration | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-07-27 08:30:00 | https://www.prnewswire.com/news-releases/abbvie-and-calico-announce-second-extension-of-collaboration-focused-on-aging-and-age-related-diseases-301341606.html | NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif. | AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-07-27 07:36:52 | https://247wallst.com/investing/2021/07/27/sp-500-dividend-yield-lowest-in-20-years-5-blue-chips-to-buy-now-with-huge-dividends/ | Time and time again, the Wall Street pundits say interest rates are going higher, and time and time again they plunge lower. | S&P 500 Dividend Yield Lowest in 20 Years: 5 Blue Chips to Buy Now With Huge Dividends | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-07-26 19:09:35 | https://www.zacks.com/stock/news/1767932/abbvie-abbv-stock-sinks-as-market-gains-what-you-should-know | AbbVie (ABBV) closed at $117.79 in the latest trading session, marking a -0.34% move from the prior day. | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-07-25 11:31:00 | https://www.prnewswire.com/news-releases/new-data-presented-on-the-safety-and-efficacy-of-investigational-agn-190584-as-a-potential-novel-treatment-for-presbyopia-a-common-and-progressive-eye-condition-301339937.html | NORTH CHICAGO, Ill., July 25, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treat... | New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-07-25 05:55:00 | https://www.fool.com/investing/2021/07/25/3-dividend-stocks-to-buy-hand-over-fist-if-the-mar/ | You'll be able to lock in fantastic dividend yields if you do. | 3 Dividend Stocks to Buy Hand Over Fist If the Market Crashes | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-07-24 06:04:00 | https://www.fool.com/investing/2021/07/24/3-value-stocks-to-buy-for-the-second-half-of-2021/ | These stocks are cheap, but their underlying businesses are solid. | 3 Value Stocks to Buy for the Second Half of 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-07-23 12:37:00 | https://www.prnewswire.com/news-releases/dalvance-dalbavancin-receives-fda-approval-to-treat-acute-bacterial-skin-and-skin-structure-infections-in-pediatric-patients-301340347.html | NORTH CHICAGO, Ill., July 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth. | DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-07-22 08:34:45 | https://seekingalpha.com/article/4440565-pre-august-billionaire-flash-63-stocks-41-dividends-3-buys | Kiplinger Investing publishes opportune buy-lists for investors online. Two billionaire stock-lists by Dan Burrows included 50 published 12/8/20, with 30 more out June 1, 2021. Seventeen were duplicated, leaving 63. 41 of these 63 billionaire-held stocks pay dividends. As of 7/20/21, the top-ten ranged 2.52%-6.22% by a... | Pre-August Billionaire Flash: 63 Stocks, 41 Dividends, 3 Buys | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-07-21 13:09:12 | https://www.zacks.com/stock/news/1765168/why-abbvie-abbv-is-a-great-dividend-stock-right-now | Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? | Why AbbVie (ABBV) is a Great Dividend Stock Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-07-21 12:23:09 | https://www.zacks.com/stock/news/1765072/here-s-why-abbvie-abbv-is-a-strong-momentum-stock | The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. | Here's Why AbbVie (ABBV) is a Strong Momentum Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-07-21 11:37:06 | https://www.zacks.com/stock/news/1765078/abbvie-abbv-venclexta-gets-breakthrough-therapy-tag-for-mds | The FDA grants a Breakthrough Therapy designation to AbbVie's (ABBV) Venclexta in combination with azacitidine for treating adult patients with higher risk myelodysplastic syndrome. | AbbVie (ABBV) Venclexta Gets Breakthrough Therapy Tag for MDS | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-07-21 07:15:40 | https://247wallst.com/investing/2021/07/21/5-highest-yielding-dividend-aristocrat-stocks-to-buy-now-as-interest-rates-continue-to-plunge/ | We have covered the Dividend Aristocrats stocks for years here at 24/7 Wall St. So it was kind of a seismic shock back in the spring when AT&T, a long-time charter member of the list, announced it would be cutting its cherished dividend. | 5 Highest Yielding Dividend Aristocrat Stocks to Buy Now as Interest Rates Continue to Plunge | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-07-21 05:59:08 | https://www.benzinga.com/general/biotech/21/07/22077335/abbvie-roches-venclexta-receives-breakthrough-therapy-tag-in-high-risk-myelodysplastic-syndromes | The FDA has granted Breakthrough Therapy Designation (BTD) to Venclexta (venetoclax) combined with azacitidine for the potential treatment of adult patients with myelodysplastic syndromes (MDS). Venclexta is being developed by AbbVie Inc (NYSE: ABBV) and Roche Holdings AG (OTC: RHHBY). | AbbVie - Roche's Venclexta Receives Breakthrough Therapy Tag In High-Risk Myelodysplastic Syndromes | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-07-21 01:00:00 | https://www.prnewswire.com/news-releases/venetoclax-venclexta-granted-us-fda-breakthrough-therapy-designation-btd-in-higher-risk-myelodysplastic-syndrome-mds-301338030.html | NORTH CHICAGO, Ill., July 21, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation (BTD) to venetoclax (VENCLEXTA®) in combination with azacitidine for the potential treatment of adult patients with previously untreated inte... | Venetoclax (VENCLEXTA®) Granted US FDA Breakthrough Therapy Designation (BTD) in Higher Risk Myelodysplastic Syndrome (MDS) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-07-19 19:03:47 | https://www.zacks.com/stock/news/1763820/abbvie-abbv-dips-more-than-broader-markets-what-you-should-know | In the latest trading session, AbbVie (ABBV) closed at $115.42, marking a -1.77% move from the previous day. | AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-07-19 12:59:24 | https://www.zacks.com/stock/news/1763659/abbvie-abbv-rinvoq-dermatitis-snda-decision-delayed-by-fda | The FDA will not meet its action dates for AbbVie's (ABBV) sNDA for JAK inhibitor drug, Rinvoq (upadacitinib), for moderate to severe atopic dermatitis. | AbbVie (ABBV) Rinvoq Dermatitis' sNDA Decision Delayed by FDA | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-07-19 12:40:06 | https://investorplace.com/2021/07/3-high-yield-dividend-stocks-aristocrats-to-buy-now/ | These dividend stocks are standouts from the Dividend Aristocrats list. They have yields higher than 4% and can consistently raise dividends. | 3 High-Yield Dividend Aristocrats To Buy Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-07-18 09:01:00 | https://www.fool.com/investing/2021/07/18/4-large-cap-healthcare-stocks-youll-want-on-your-r/ | There are important things to watch with each of these stocks. | 4 Large-Cap Healthcare Stocks You'll Want on Your Radar for the Second Half of 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-07-17 06:22:00 | https://www.fool.com/investing/2021/07/17/will-this-biopharma-company-continue-to-crush-it/ | Migraine sufferers certainly hope so. | Will This Biopharma Company Continue to Crush It? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-07-16 13:57:00 | https://www.benzinga.com/general/biotech/21/07/22022984/abbvie-lilly-atopic-dermatitis-treatments-hit-with-further-delays-with-fda | AbbVie Inc (NYSE: ABBV) and Eli Lilly And Co (NYSE: LLY) will have to keep waiting for a chance for their JAK inhibitors in atopic dermatitis to see the market. The companies separately said on Friday that the FDA again delayed decisions over their applications for Rinvoq (upadacitinib) and Olumiant (baricitinib) in mo... | AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-07-16 12:10:20 | https://investorplace.com/2021/07/7-best-dividend-stocks-to-buy-to-juice-your-portfolio-yield/ | These dividend stocks are fundamentally strong companies with solid earnings bases. Thus, their dividend payouts are safe and sustainable. | 7 Best Dividend Stocks to Buy to Juice Your Portfolio Yield | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Forbes | 2021-07-16 09:00:00 | https://www.forbes.com/sites/greatspeculations/2021/07/16/heres-why-abbvie-stock-will-likely-see-higher-levels/ | We believe that the stock price of AbbVie has more room for growth from its current levels of $117. ABBV stock is up 95% from the levels of around $60 it was at on March 23, 2020, when the broader markets made a bottom. | Here's Why AbbVie Stock Will Likely See Higher Levels | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-07-16 08:30:00 | https://www.prnewswire.com/news-releases/abbvie-provides-update-regarding-rinvoq-upadacitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-the-us-301335375.html | NORTH CHICAGO, Ill., July 16, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) did not meet the Prescription Drug User Fee Act (PDUFA) action date for the supplemental New Drug Application (sNDA) for RINVOQ® (upadacitinib) for the treatment of adults and adolescents w... | AbbVie Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S. | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-07-16 05:22:02 | https://seekingalpha.com/article/4439491-3-high-dividends-im-buying-hand-over-fist | 3 High Dividends I'm Buying Hand Over Fist | 3 High Dividends I'm Buying Hand Over Fist | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-07-16 03:08:24 | https://seekingalpha.com/article/4439478-buffett-46-july-holdings-include-28-dividend-payers | This Buffett holdings list from Kiplinger first appeared 5/17/21 on line. YCharts and Dogs of The Dow also track this Buffett/Berkshire Batch. Here is your update from 7/13/21 YCharts data. 8 of 46 current Berkshire Hathaway owned stocks pay dividends. As of 7/13/21 the top ten ranged 2.72%-5.16% by annual yield and ra... | Buffett 46 July Holdings Include 28 Dividend Payers | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2021-07-14 08:00:14 | https://marijuanastocks.com/best-medical-marijuana-stock-to-buy-in-2021-2-with-long-term-potential-right-now/ | Big Pharmaceutical Companies That Are Top Medicinal Cannabis Stocks The post Best Medical Marijuana Stock To Buy In 2021? 2 With Long Term Potential Right Now appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | Best Medical Marijuana Stock To Buy In 2021? 2 With Long Term Potential Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-07-12 19:20:36 | https://www.zacks.com/stock/news/1760560/abbvie-abbv-outpaces-stock-market-gains-what-you-should-know | AbbVie (ABBV) closed the most recent trading day at $117.63, moving +0.9% from the previous trading session. | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Kiplinger | 2021-07-12 14:28:50 | https://www.kiplinger.com/investing/stocks/dividend-stocks/603105/high-quality-stocks-with-dividend-yields-of-4-or-more | There's no shortage of stocks with dividends these days, but not all of them are worth chasing. Here's a list of top-rated, high-yielding names to consider. | 10 High-Quality Stocks With Dividend Yields of 4% or More | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-07-11 09:00:00 | https://seekingalpha.com/article/4438608-upcoming-ex-dividend-dates-july-13-26-2021 | This article series presents upcoming ex-dividend dates. We provide a summary table with relevant data and key statistics, including the next payout and pay date. | Upcoming Ex-Dividend Dates: July 13-26, 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-07-11 05:16:34 | https://seekingalpha.com/article/4438629-caribou-bioscience-gene-editing-pioneer-files-ipo-to-raise-100m-crbu | Caribou Bioscience: Gene Editing Pioneer Files IPO To Raise $100M | Caribou Bioscience: Gene Editing Pioneer Files IPO To Raise $100M | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-07-09 01:31:03 | https://www.zacks.com/stock/news/1759454/3-big-drugmakers-to-buy-ahead-of-the-q2-earnings-season-revised | AstraZeneca (AZN), AbbVie (ABBV) and Bayer (BAYRY) are three large drug sector companies worth buying now. | 3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season (Revised) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-07-08 14:19:51 | https://www.gurufocus.com/news/1471361/abbvie-on-cusp-of-getting-approval-for-rinvoq-in-ulcerative-colitis | AbbVie Inc.'s ( ABBV , Financial) next-generation immunology drug is closer to fulfilling its promise to help ease the pain caused by the imminent loss of patent protection for the company's multibillion-dollar blockbuster Humira. | AbbVie on Cusp of Getting Approval for Rinvoq in Ulcerative Colitis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-07-08 01:09:59 | https://seekingalpha.com/article/4438239-10-picks-for-july | The stock market is overvalued, but we can still try to find investments without overpaying. A first category of stocks are recession-proof and undervalued companies like Walgreens Boots Alliance, Henkel, Amgen or AbbVie. | 10 Picks For July | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-07-07 12:47:17 | https://seekingalpha.com/article/4438183-abbvie-primed-to-climb-wall-of-worry | AbbVie's cashflow and dividend payout continue to get no respect from the market. AbbVie was recently scapegoated over patent and tax laws, which was a headwind, but I believe this set up a classic wall of worry. | AbbVie Is Primed To Climb A Wall Of Worry | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-07-07 08:00:00 | https://www.prnewswire.com/news-releases/abbvie-to-host-second-quarter-2021-earnings-conference-call-301326236.html | NORTH CHICAGO, Ill., July 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2021 financial results on Friday, July 30, 2021, before the market opens. | AbbVie to Host Second-Quarter 2021 Earnings Conference Call | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-07-07 06:10:00 | https://www.fool.com/investing/2021/07/07/got-5000-buy-and-hold-these-3-value-stocks-for-yea/ | Looking to buy and forget a stock? Look no further. | Got $5,000? Buy and Hold These 3 Value Stocks for Years | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-07-06 10:31:11 | https://www.zacks.com/stock/news/1758108/3-big-drugmakers-to-buy-ahead-of-the-q2-earnings-season | AstraZeneca (AZN), AbbVie (ABBV) and Bayer (BAYRY) are three large drug sector companies worth buying now. | 3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-07-05 18:47:25 | https://www.zacks.com/stock/news/1757765/abbvie-abbv-outpaces-stock-market-gains-what-you-should-know | AbbVie (ABBV) closed at $115.17 in the latest trading session, marking a +0.8% move from the prior day. | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-07-05 15:36:27 | https://seekingalpha.com/article/4437916-upcoming-ex-dividend-dates-july-6-july-19-2021 | We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics. | Upcoming Ex-Dividend Dates: July 6-July 19, 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-07-05 12:47:21 | https://www.zacks.com/stock/news/1757674/why-abbvie-abbv-is-a-top-dividend-stock-for-your-portfolio | Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? | Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-07-05 12:02:09 | https://www.zacks.com/stock/news/1757653/is-abbvie-abbv-outperforming-other-medical-stocks-this-year | Is (ABBV) Outperforming Other Medical Stocks This Year? | Is AbbVie (ABBV) Outperforming Other Medical Stocks This Year? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-07-04 07:48:49 | https://seekingalpha.com/article/4437771-abbvie-the-path-to-30-percent-annual-returns | AbbVie continually trades at a discounted valuation over fears that its loss of Humira exclusivity in 2023 will have a significant negative impact on the company. AbbVie's replacements for Humira (Skyrizi and Rinvoq) are rapidly growing and will eventually make up for the drop in sales as generics begin to pressure Hum... | AbbVie: The Path To 30% Annual Returns | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-07-04 07:04:48 | https://seekingalpha.com/article/4437768-102-top-dividend-stocks-on-earth-july-update | Kiplinger "insights for investors" online, first listed 91 "Top Dividend Stocks From Around The World" 7/13/20. Two recent Kiplinger articles provided 102 Top Dividend Stocks on Earth as of 7/1/21. 39 European “Dividend Aristocrats,” show 10 years of stable or increasing dividends; 65 S&P 500 Aristocrats show 25 years ... | 102 'Top Dividend Stocks On Earth' July Update | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-07-03 06:04:00 | https://www.fool.com/investing/2021/07/03/these-covid-therapies-appear-to-be-the-best-and-wo/ | Here's how several leading COVID-19 antibody therapies compare based on pre-clinical testing. | These COVID Therapies Appear to Be the Best and Worst at Treating New Variants | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-07-02 05:52:00 | https://www.fool.com/investing/2021/07/02/got-400-3-fantastic-dividend-stocks-to-buy-right-n/ | You'll get more than just dividends with these three stocks. | Got $400? 3 Fantastic Dividend Stocks to Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-06-30 10:45:42 | https://www.fool.com/investing/2021/06/30/abbvie-is-the-price-right-for-long-term-investment/ | The pharma giant's stock is up 18% in the past year. Have investors missed the boat or is the stock still a buy? | AbbVie: Is the Price Right for Long-Term Investment? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-06-30 08:15:00 | https://seekingalpha.com/article/4437199-abbvie-firing-on-all-cylinders | AbbVie is a premier dividend stock with a superior and safe dividend. | AbbVie Is Firing On All Cylinders | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-06-29 15:24:57 | https://www.benzinga.com/general/biotech/21/06/21771940/new-york-takes-drugmakers-drug-retailers-to-legal-trial-over-opioid | Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International Plc (NASDAQ: ENDP), and AbbVie Inc's (NYSE: ABBV) Allergan misleadingly marketed opioid drugs as having a low addiction risk, a lawyer for a New York county told jurors, urging them to hold the companies liable. Jayne Conroy, representing Suffolk Count... | New York Takes Drugmakers, Drug Retailers To Legal Trial Over Opioid | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-06-28 18:47:25 | https://www.zacks.com/stock/news/1755257/abbvie-abbv-gains-but-lags-market-what-you-should-know | AbbVie (ABBV) closed at $113 in the latest trading session, marking a +0.02% move from the prior day. | AbbVie (ABBV) Gains But Lags Market: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-06-28 09:01:11 | https://www.zacks.com/stock/news/1754862/abbvies-abbv-rinvoq-snda-decision-delayed-by-the-fda | The FDA will not meet its action dates for AbbVie's (ABBV) sNDAs for JAK inhibitor drug, Rinvoq (upadacitinib), for active psoriatic arthritis and active ankylosing spondylitis in adults. | AbbVie's (ABBV) Rinvoq sNDA Decision Delayed by the FDA | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-06-25 13:33:23 | https://www.benzinga.com/general/biotech/21/06/21723762/fda-to-miss-action-dates-for-abbvies-upadacitinib-application-for-psoriatic-arthritis-ankylosing- | The FDA will not meet action dates for AbbVie Inc's (NYSE:ABBV) supplemental marketing applications for Rinvoq (upadacitinib) for active psoriatic arthritis and adults with active ankylosing spondylitis. The FDA cited its ongoing review of Pfizer Inc's (NYSE:PFE) post-marketing study, ORAL Surveillance, evaluating tof... | FDA To Miss Action Dates For AbbVie's Upadacitinib Application For Psoriatic Arthritis, Ankylosing Spondylitis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2021-06-25 09:00:26 | https://marijuanastocks.com/abbv-provides-update-regarding-rinvoq/ | AbbVie Provides Update Regarding RINVOQ® (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis… The post AbbVie (ABBV) Provides Update Regarding RINVOQ® appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | AbbVie (ABBV) Provides Update Regarding RINVOQ® | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-06-25 08:30:00 | https://www.prnewswire.com/news-releases/abbvie-provides-update-regarding-rinvoq-upadacitinib-in-psoriatic-arthritis-and-ankylosing-spondylitis-in-the-us-301319940.html | NORTH CHICAGO, Ill., June 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that the FDA will not meet the Prescription Drug User Fee Act (PDUFA) action dates for the supplemental New Drug Applications (sNDAs) for RINVOQ® (upadacitinib... | AbbVie Provides Update Regarding RINVOQ® (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis in the U.S. | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-06-25 07:50:45 | https://investorplace.com/2021/06/3-high-yield-dividend-stocks-with-secure-payouts/ | The advantages these companies bring to the table makes their payouts reliable. That makes them excellent dividend stocks to buy. | 3 High-Yield Stocks With Secure Payouts | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-06-25 02:30:00 | https://www.prnewswire.com/news-releases/chmp-recommends-approval-of-rinvoq-upadacitinib-for-the-treatment-of-atopic-dermatitis-301319936.html | NORTH CHICAGO, Ill., June 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of RINVOQ® (upadacitinib), an oral, selective and reversible JAK inhibitor, for the expa... | CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.